×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Exchange
/
Drug Targets
🎯 Drug Targets
Browse 16 drug targets with druggability analysis, composite scores, and clinical context
16
Targets
0
High Druggability
0.48
Avg Score
15
Target Classes
Druggability Distribution
High:
0
Medium:
0
Low:
16
Unknown:
0
Avg druggability score:
0.298
Clinical Pipeline
Approved:
3
Phase III:
0
Phase II:
7
Phase I:
6
Preclinical:
0
Total compounds:
19
· Approved:
3
Search
Class
All Classes
Enzyme
(35)
Signaling Protein
(25)
Structural Protein
(17)
Protein
(16)
Gpcr
(13)
Ion Channel
(12)
Transcription Factor
(11)
Receptor
(11)
Ligand
(10)
Transporter
(8)
Epigenetic Regulator
(8)
Kinase
(7)
Protease
(4)
Other
(4)
Chaperone
(4)
Druggability
All Druggability
Low
(100)
Medium
(62)
High
(14)
Undruggable
(6)
other
(3)
Sort
Score
Druggability
Gene A-Z
Market Price
Filtered by: class=signaling_protein, druggability=Low — 16 results
MIRO1
Mitochondrial Rho GTPase 1
Phase 2
Signaling Protein
Low Druggability
Score
0.63
Drug.
0.29
Safety
0.40
Drugs
4
Hyps
5
Papers
29
MIRO1-targeting drugs modulate GTPase activity to enhance mitochondrial transport along axons and improve mitochondrial quality control through selective autophagy. By regulating MIRO1's interaction with kinesin motor proteins and PINK1-mediated mitophagy, these compounds restore energy homeostasis and reduce neuronal stress in neurodegenerative diseases.
C1Q
Complement C1q
Phase 4
Signaling Protein
Low Druggability
Score
0.62
Drug.
0.36
Safety
0.45
Drugs
1
Hyps
58
Papers
22
Complement cascade inhibitor or antibody-mediated neutralization
STING1
Stimulator of interferon genes protein 1
Phase 2
Signaling Protein
Low Druggability
Score
0.60
Drug.
0.40
Safety
0.40
Drugs
2
Hyps
1
Papers
22
Small molecule agonists or antagonists of cGAS-STING pathway activation
RAB27A
Ras-related protein Rab-27A
Phase 2
Signaling Protein
Low Druggability
Score
0.59
Drug.
0.35
Safety
0.40
Drugs
1
Hyps
1
Papers
28
RAB27A inhibitors would block GTP binding or GTPase activity, preventing the recruitment of effector proteins required for vesicular trafficking and exosome biogenesis. This would reduce the release of extracellular vesicles and potentially modulate intercellular communication in disease states involving excessive exosome-mediated signaling or pathological cargo transfer.
C1QA
Complement C1q A Chain
Phase 2
Signaling Protein
Low Druggability
Score
0.58
Drug.
0.41
Safety
0.45
Drugs
1
Hyps
5
Papers
44
Complement cascade inhibitor or antibody-mediated neutralization
ANXA1
Annexin A1
Phase 4
Signaling Protein
Low Druggability
Score
0.53
Drug.
0.41
Safety
0.60
Drugs
1
Hyps
1
Papers
25
Calcium-dependent phospholipid binding protein modulator
SYNCRIP
Heterogeneous nuclear ribonucleoprotein Q
Phase 2
Signaling Protein
Low Druggability
Score
0.50
Drug.
0.32
Safety
0.40
Drugs
2
Hyps
1
Papers
30
Small molecule or antisense-based inhibitors would disrupt SYNCRIP's RNA-binding capability, reducing its ability to facilitate mRNA transport and local protein synthesis, potentially modulating disease pathways in neurological disorders or cancers where SYNCRIP dysfunction is implicated.
PYCARD
Apoptosis-associated speck-like protein containing
Phase 2
Signaling Protein
Low Druggability
Score
0.50
Drug.
0.35
Safety
0.40
Drugs
1
Hyps
1
Papers
0
PYCARD acts as a critical adaptor protein in inflammasome activation, facilitating pro-inflammatory caspase-1 recruitment and subsequent IL-1β/IL-18 processing, which contributes to neuroinflammatory processes in neurodegenerative conditions like Alzheimer's and Parkinson's disease. Its protein-protein interaction domains mediate inflammatory signal transduction, potentially amplifying neuronal damage through excessive immune response activation.
CELL-TYPE-SPECIFICESSENTIALGENES
CELL-TYPE-SPECIFICESSENTIALGENES
Phase 1
Signaling Protein
Low Druggability
Score
0.48
Drug.
0.30
Safety
0.50
Drugs
0
Hyps
1
Papers
12
Prioritized from 1 SciDEX hypotheses, including: Context-Dependent CRISPR Activation in Specific Neuronal Subtypes
RELN
Reelin
Phase 4
Signaling Protein
Low Druggability
Score
0.48
Drug.
0.33
Safety
0.50
Drugs
4
Hyps
1
Papers
31
Drugs targeting RELN would primarily work by enhancing reelin expression or signaling through its receptors (VLDLR and ApoER2) to promote neuronal migration, synaptic plasticity, and cognitive function. Alternatively, pathway modulators could enhance downstream signaling cascades (Dab1-mediated pathways) to compensate for reelin deficiency or dysfunction.
LAMP2B
LAMP2B
Phase 1
Signaling Protein
Low Druggability
Score
0.41
Drug.
0.40
Safety
0.30
Drugs
0
Hyps
1
Papers
7
Prioritized from 1 SciDEX hypotheses, including: Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitochondrial Delivery
DISEASE-CAUSINGMUTATIONSWITHINTEGRATEDREPORTERS
DISEASE-CAUSINGMUTATIONSWITHINTEGRATEDREPORTERS
Phase 1
Signaling Protein
Low Druggability
Score
0.36
Drug.
0.20
Safety
0.20
Drugs
0
Hyps
1
Papers
7
Prioritized from 1 SciDEX hypotheses, including: Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring
SYNTHETICFUSIONPROTEINS
SYNTHETICFUSIONPROTEINS
Phase 1
Signaling Protein
Low Druggability
Score
0.36
Drug.
0.10
Safety
0.20
Drugs
0
Hyps
1
Papers
7
Prioritized from 1 SciDEX hypotheses, including: Synthetic Biology Approach: Designer Mitochondrial Export Systems
PITX3
PITX3
Phase 1
Signaling Protein
Low Druggability
Score
0.35
Drug.
0.10
Safety
0.30
Drugs
0
Hyps
1
Papers
7
Prioritized from 1 SciDEX hypotheses, including: Programmable Neuronal Circuit Repair via Epigenetic CRISPR
NEURONALIDENTITYTRANSCRIPTIONFACTORS
NEURONALIDENTITYTRANSCRIPTIONFACTORS
Phase 1
Signaling Protein
Low Druggability
Score
0.35
Drug.
0.10
Safety
0.30
Drugs
0
Hyps
1
Papers
7
Prioritized from 1 SciDEX hypotheses, including: Programmable Neuronal Circuit Repair via Epigenetic CRISPR
PVALB
Parvalbumin
Phase 2
Signaling Protein
Low Druggability
Score
0.33
Drug.
0.34
Safety
0.30
Drugs
2
Hyps
1
Papers
0
No known druggable mechanism